Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025
VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases, including cancer, inflammation, and autoimmune disease, today announced that management will report its first quarter 2025 financial results after market close on May 8, 2025. Following the announcement, management will host a conference call and webcast to discuss financial results and provide a corporate update on May 8, 2025 at 4:30 pm Eastern Time.
The event will be webcast live with dial-in details and webcast replays available on Zymeworks' website at https://ir.zymeworks.com/events-and-presentations.
About Zymeworks Inc.
Zymeworks is a global clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, multifunctional biotherapeutics. Zymeworks' mission is to make a meaningful difference in the lives of people impacted by difficult-to-treat conditions such as cancer, inflammation, and autoimmune disease. The Company's complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. Zymeworks engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company's proprietary Azymetric™ technology. Zymeworks has entered into separate agreements with BeiGene, Ltd. (BeiGene) and Jazz Pharmaceuticals Ireland Limited (Jazz Pharmaceuticals), granting each exclusive rights to develop and commercialize zanidatamab in different territories. The U.S. FDA granted accelerated approval of Ziihera® (zanidatamab-hrii) 50mg/mL for injection for intravenous use for the treatment of adults with previously-treated, unresectable or metastatic HER2-positive (IHC 3+) second-line biliary tract cancer (BTC). Ziihera® is the first and only dual HER2-targeted bispecific antibody approved for HER2-positive BTC in the U.S. Zanidatamab is currently under regulatory review in the EU and China for second-line BTC and is being evaluated in multiple global clinical trials as a potential best-in-class treatment for patients with multiple HER2-expressing cancers. Zymeworks is rapidly advancing a robust pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. Phase 1 studies for ZW171 and ZW191 are now actively recruiting with an investigational new drug application for ZW251 planned for mid-2025. In addition to Zymeworks' pipeline, its therapeutic platforms have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X.
Contacts:
Investor Inquiries:Shrinal InamdarSenior Director, Investor Relations(604) 678-1388ir@zymeworks.com
Media Inquiries:Diana PapoveSenior Director, Corporate Communications(604) 678-1388media@zymeworks.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Freeport-McMoRan (FCX) Rises But Trails Market: What Investors Should Know
Freeport-McMoRan (FCX) ended the recent trading session at $40.24, demonstrating a +0.22% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.58% for the day. Elsewhere, the Dow saw an upswing of 0.51%, while the tech-heavy Nasdaq appreciated by 0.81%. Shares of the mining company have appreciated by 7.5% over the course of the past month, outperforming the Basic Materials sector's gain of 3.65% and the S&P 500's gain of 4.61%. The upcoming earnings release of Freeport-McMoRan will be of great interest to investors. On that day, Freeport-McMoRan is projected to report earnings of $0.47 per share, which would represent year-over-year growth of 2.17%. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $6.93 billion, up 4.69% from the year-ago period. For the full year, the Zacks Consensus Estimates project earnings of $1.67 per share and a revenue of $27.03 billion, demonstrating changes of +12.84% and +6.2%, respectively, from the preceding year. It's also important for investors to be aware of any recent modifications to analyst estimates for Freeport-McMoRan. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the company's business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has moved 2.63% higher. At present, Freeport-McMoRan boasts a Zacks Rank of #3 (Hold). Looking at its valuation, Freeport-McMoRan is holding a Forward P/E ratio of 24.11. For comparison, its industry has an average Forward P/E of 22.61, which means Freeport-McMoRan is trading at a premium to the group. It's also important to note that FCX currently trades at a PEG ratio of 0.79. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The average PEG ratio for the Mining - Non Ferrous industry stood at 0.85 at the close of the market yesterday. The Mining - Non Ferrous industry is part of the Basic Materials sector. This group has a Zacks Industry Rank of 59, putting it in the top 24% of all 250+ industries. The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Don't forget to use to keep track of all these stock-moving metrics, and others, in the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Freeport-McMoRan Inc. (FCX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Spotify (SPOT) Stock Declines While Market Improves: Some Information for Investors
Spotify (SPOT) closed the latest trading day at $671.07, indicating a -0.14% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.58%. On the other hand, the Dow registered a gain of 0.51%, and the technology-centric Nasdaq increased by 0.81%. Coming into today, shares of the music-streaming service operator had gained 5.39% in the past month. In that same time, the Computer and Technology sector gained 7.05%, while the S&P 500 gained 4.61%. The investment community will be paying close attention to the earnings performance of Spotify in its upcoming release. It is anticipated that the company will report an EPS of $2.27, marking a 58.74% rise compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $4.78 billion, indicating a 16.67% growth compared to the corresponding quarter of the prior year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $9.72 per share and a revenue of $19.9 billion, signifying shifts of +63.36% and +17.37%, respectively, from the last year. Investors should also note any recent changes to analyst estimates for Spotify. These revisions help to show the ever-changing nature of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.63% lower. At present, Spotify boasts a Zacks Rank of #3 (Hold). In terms of valuation, Spotify is presently being traded at a Forward P/E ratio of 69.13. This signifies a premium in comparison to the average Forward P/E of 28.89 for its industry. It is also worth noting that SPOT currently has a PEG ratio of 1.68. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Internet - Software was holding an average PEG ratio of 2.21 at yesterday's closing price. The Internet - Software industry is part of the Computer and Technology sector. Currently, this industry holds a Zacks Industry Rank of 54, positioning it in the top 22% of all 250+ industries. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Spotify Technology (SPOT) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Alphabet (GOOGL) Stock Slides as Market Rises: Facts to Know Before You Trade
Alphabet (GOOGL) ended the recent trading session at $166.18, demonstrating a -1.69% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily gain of 0.58%. Elsewhere, the Dow saw an upswing of 0.51%, while the tech-heavy Nasdaq appreciated by 0.81%. Shares of the internet search leader witnessed a gain of 2.94% over the previous month, trailing the performance of the Computer and Technology sector with its gain of 7.05% and the S&P 500's gain of 4.61%. The upcoming earnings release of Alphabet will be of great interest to investors. The company's upcoming EPS is projected at $2.12, signifying a 12.17% increase compared to the same quarter of the previous year. Meanwhile, our latest consensus estimate is calling for revenue of $78.86 billion, up 10.51% from the prior-year quarter. GOOGL's full-year Zacks Consensus Estimates are calling for earnings of $9.47 per share and revenue of $323.73 billion. These results would represent year-over-year changes of +17.79% and +9.69%, respectively. It's also important for investors to be aware of any recent modifications to analyst estimates for Alphabet. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 0.46% higher. Currently, Alphabet is carrying a Zacks Rank of #3 (Hold). Looking at valuation, Alphabet is presently trading at a Forward P/E ratio of 17.85. This valuation marks a discount compared to its industry's average Forward P/E of 17.99. Also, we should mention that GOOGL has a PEG ratio of 1.15. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Internet - Services was holding an average PEG ratio of 1.35 at yesterday's closing price. The Internet - Services industry is part of the Computer and Technology sector. With its current Zacks Industry Rank of 91, this industry ranks in the top 37% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. You can find more information on all of these metrics, and much more, on Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Alphabet Inc. (GOOGL) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
